To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.
The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;
Age 18-85 years old, male or female;
Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;
ECOG score is 0-3 points;
Patients with a history or allergic constitution to any component of the developer, including alcohol;
pregnant or lactating women;
Patients with mental illness or related history;
Patients who cannot or cannot undergo a PET/CT scan;
Single group
68Ga-FAPI-JNU
DrugPatients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
Evaluation of the distribution of 68Ga-FAPI-JNU in tumors, metastases and normal tissues
CT and PET scans were performed on the patients injected with 68Ga-FAPI-JNU. After image reconstruction and PET/CT image fusion, the biological distribution of 68Ga-FAPI-JNU in the primary tumor, metastatic tumor and various tissues and organs of the patients was evaluated by radioactive uptake value (standardized uptake value, SUV)
Click on the lead sponsor to view all of their trials.
